Double Bond Pharmaceutical AB has started a scientific and technological collaboration with N. N. Alexandrov National Cancer Centre of Belarus
DBP and N. N. Alexandrov National Cancer Centre of Belarus will initiate the collaboration program immediately. The main goal for DBP is to get access to the knowledge and resources that are relevant to the development of DBPs front-line products - drugs SA-033 against liver cancer and Temodex against brain cancer - already from December 2016.
"We are excited to be part of a long-term collaboration with N. N. Alexandrov National Cancer Centre of Belarus. This governmental organization can be a great resource and advisory board for the DBP within some clinical and technical questions to ensure a time efficient product development and direct access to valuable knowledge and resources," says Igor Lokot, CEO of DBP. "The competitive price and the innovative collaborative approach will also allow us to further reduce our burn rate and finantial burden in the short term, while securing the company's value on the market in the long term."
The partnership includes access to the scientific and clinical knowledge, experience and resources, and technical resources for the preclinical and clinical drug development.
N.N. Alexandrov National Cancer Centre of Belarus:
N.N. Alexandrov National Cancer Centre is the leading cancer centre in Belarus. It provides the whole scope of services in the field of diagnosis and treatment of malignant tumors.
N.N. Alexandrov National Cancer Centre is also the greatest medical research institution of the Republic of Belarus. It provides free of charge examination and treatment of Belarusian citizens with malignant tumors and renders paid medical services for foreign citizens and Belarusian citizens without malignant diseases.
For more information, read here.
SA-033 is the first drug candidate that DBP has developed based on company’s own innovative drug delivery technology BeloGal®. Using this technology, doxorubicin is accurately and specifically deiivered to the liver, which increases the concentration of the active substance in the tumor-affected target organ (in this case liver), improves efficiency and reduces the toxic side effects that are common in systemic (whole body) chemotherapy. SA-033 enters Phase I clinical trials during the first half of 2017, meaning that it will be tested in humans for the first time. Because SA-033 has received Orphan Drug status from the EMA it may be sufficient with the Phase I and Phase II clinical trials to receive a marketing authorization for this product. This is called Conditional Approval and allows to perform the most costly and time-consuming clinical phase, Phase III, after the drug is allowed to be marketed. The goal is that SA-033 can reach the European market already in 2019.
BeloGal® is DBP’s innovative drug delivery platform that facilitates a simple and controlled distribution of a given drug exactly to the diseased organ.
Temodex, which is a locally acting formulation of temozolomide, was developed by RI PCP in Minsk, Belarus, and is registered for marketing within Belarus since 2014 as the first-line treatment of glioblastoma. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. Find out more here.
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. DBP acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015. The company was granted Orphan Drug Designation status by EMA for Temodex in July 2016.